Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SAHA decreases HDAC 2 and 4 levels in vivo and improves molecular phenotypes in the R6/2 mouse model of Huntington's disease.

PloS one - 1 Jan 2011

Mielcarek Michal, Benn Caroline L, Franklin Sophie A, Smith Donna L, Woodman Ben, Marks Paul A, Bates Gillian P

Abstract excerpt

Huntington's disease (HD) is a progressive neurological disorder for which there are no disease-modifying treatments. Transcriptional dysregulation is a major molecular feature of HD, which significantly contributes to disease progression. Therefore, the development of histone deacetylase (HDAC) inhibitors as therapeutics for HD has been energetically pursued. Suberoylanilide hydroxamic acid (SAHA) - a class I...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain-Derived Neurotrophic Factor
Share to Disease Models, Animal

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Down-Regulation

Share to Histone Deacetylases

Share to Huntington Disease

Share to Hydroxamic Acids

Share to Vorinostat

Source

Open in PubMed Open full text

Identifiers

PMID: 22140466
DOI: 10.1371/journal.pone.0027746
PMCID: PMC3225376

Genes

HDAC4
HDAC2
HDAC6
SDS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SAHA decreases HDAC 2 and 4 levels in vivo and improves molecular phenotypes in the R6/2 mouse model of Huntington's disease.PMID 22140466Read ↗

Evaluation of Histone Deacetylases as Drug Targets in Huntington’s Disease modelsStudy of HDACs in brain tissues from R6/2 and CAG140 knock-in HD mouse models and human patients and in a neuronal HD cell model.Semantic proximity Read ↗

Genetic knock-down of HDAC7 does not ameliorate disease pathogenesis in the R6/2 mouse model of Huntington's disease.Semantic proximity Read ↗

Genetic knock-down of HDAC3 does not modify disease-related phenotypes in a mouse model of Huntington's disease.Semantic proximity Read ↗

The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice.Semantic proximity Read ↗

Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease.Semantic proximity Read ↗

HDAC4 reduction: a novel therapeutic strategy to target cytoplasmic huntingtin and ameliorate neurodegeneration.Semantic proximity Read ↗

Selective inhibition of histone deacetylase 1 and 3 improves motor phenotype and alleviates transcriptional dysregulation in Huntington’s disease miceSemantic proximity Read ↗

HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs?Semantic proximity Read ↗

SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy.Semantic proximity Read ↗

The Effects of Selective Inhibition of Histone Deacetylase 1 and 3 in Huntington’s Disease MiceSemantic proximity Read ↗

Histone deacetylases as targets for the treatment of human neurodegenerative diseasesSemantic proximity Read ↗

Putting the ‘HAT’ back on survival signalling: the promises and challenges of HDAC inhibition in the treatment of neurological conditionsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.